Table 1.
Baseline patient and disease characteristics (n = 11).
| Characteristics | No./proportion (%); or Median [Range] | |
|---|---|---|
| Age in years | 55 [19–70] | |
| White blood cell count, K/microL | 1.8 [0.7–8.9] | |
| Platelet count, K/microL | 28 [3–146] | |
| Peripheral blood blast percentage, % | 14 [2–50] | |
| Lactate dehydrogenase, IU/L | 461 [338–1172] | |
| Bone marrow blast percentage, % | 27 [7–82] | |
| Prior therapies | 1 [1–3] | |
| Prior transplant | 3 (27) | |
| Secondary AML | 0 (0) | |
| Intermediate-dose cytarabine based | 5 (45) | |
| Hypomethylating therapy | 5 (45) | |
| Cytogenetics | Adverse risk | 2/10 (20) |
| Diploid | 5/10 (50) | |
| Miscellaneous | 2/10 (20) | |
| Favorable risk | 1/10 (10) | |
| RUNX1 | 2/9 (22) | |
| IDH1/2 | 2/9 (22) | |
| RAS | 1/9 (11) | |
| NPM1 | 1/9 (11) | |
| DNMT3A | 1/9 (11) | |
| TP53 | 1/9 (11) | |
| TET2 | 1/9 (11) |